- Home
- TBLA vs GHRS Comparison
TBLA vs GHRS Comparison
Compare TBLA & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TBLA | GHRS |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | United States | Ireland |
| Employees | 2000 | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 952.2M | 947.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | TBLA | GHRS |
|---|---|---|
| Price | $4.92 | $22.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $5.00 | ★ $41.38 |
| AVG Volume (30 Days) | ★ 2.9M | 193.2K |
| Earning Date | 05-06-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.63 | N/A |
| Revenue Next Year | $5.25 | N/A |
| P/E Ratio | $42.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.84 | $10.96 |
| 52 Week High | $5.26 | $24.66 |
Technical Indicators
Market Signals| Indicator | TBLA | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 68.93 | 61.36 |
| Support Level | $3.86 | $12.65 |
| Resistance Level | $5.26 | $22.88 |
| Average True Range (ATR) | 0.26 | 1.49 |
| MACD | -0.02 | -0.13 |
| Stochastic Oscillator | 77.26 | 58.59 |
Price Performance
Historical ComparisonAbout TBLA Taboola.com Ltd.
Taboola is a performance-based native advertising network designed to improve click-through rates and increase monetizable events for advertisers while generating yield for publisher websites. Taboola competes with Google, Amazon, and other advertising networks that display stories and products on websites. The company was founded in 2007 in Israel. It acquired Connexity, a retail advertising network, in 2021, and entered a partnership with Yahoo in 2022, in which it acquired exclusive native advertising rights over Yahoo digital properties in exchange for a 25% equity stake in the company.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.